Press coverage about ACADIA Pharmaceuticals (NASDAQ:ACAD) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ACADIA Pharmaceuticals earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.668239213491 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Evaluate Stock’s Volatility Before Making Any Investment Decision: ACADIA Pharmaceuticals Inc., (NASDAQ: ACAD) – Stock Watch (stocksnewstimes.com)
- Lookout For Risk Factors: ACADIA Pharmaceuticals Inc., (NASDAQ: ACAD) – Stock Watch (stocksnewstimes.com)
- ACADIA Pharmaceuticals Inc. (ACAD) moves -10.85% away from 52-Week High = Technical Facts – Voice Of Analysts (analystsbuzz.com)
- ACADIA Pharmaceuticals Inc. (ACAD) Receives Average Rating of “Buy” from Analysts (americanbankingnews.com)
- Hot Stock Analysis: ACADIA Pharmaceuticals Inc., (NASDAQ: ACAD) – Stock Watch (stocksnewstimes.com)
ACADIA Pharmaceuticals (ACAD) opened at 36.32 on Friday. The firm’s market cap is $4.45 billion. The company has a 50-day moving average of $36.99 and a 200 day moving average of $31.78. ACADIA Pharmaceuticals has a 52-week low of $20.68 and a 52-week high of $41.20.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.17. ACADIA Pharmaceuticals had a negative net margin of 485.14% and a negative return on equity of 62.08%. The business had revenue of $30.50 million during the quarter, compared to analysts’ expectations of $20.02 million. During the same quarter in the previous year, the company earned ($0.63) EPS. The business’s revenue was up 30400.0% on a year-over-year basis. On average, equities research analysts anticipate that ACADIA Pharmaceuticals will post ($2.55) EPS for the current year.
A number of research analysts have recently commented on the stock. Piper Jaffray Companies reaffirmed a “buy” rating and set a $61.00 price objective (up previously from $54.00) on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 5th. J P Morgan Chase & Co set a $50.00 price objective on shares of ACADIA Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, October 5th. JMP Securities upped their price objective on shares of ACADIA Pharmaceuticals from $47.00 to $50.00 and gave the company an “outperform” rating in a research report on Thursday, October 5th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Wednesday, August 9th. Finally, ValuEngine raised shares of ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Six investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $47.73.
In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 14,322 shares of ACADIA Pharmaceuticals stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $34.88, for a total value of $499,551.36. Following the completion of the sale, the executive vice president now owns 78,578 shares in the company, valued at approximately $2,740,800.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 78,329 shares of company stock valued at $2,957,975 in the last quarter. Corporate insiders own 22.25% of the company’s stock.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.